According to the company, the funds will be used to support the continued development of Hu5F9-G4, an antibody against CD47
, in five ongoing monotherapy Phase 1b and combination therapy Phase 1b/2 trials, in patients with solid tumors, leukemia or lymphoma.
sends a "Do not eat me" signal to block immune cells from killing the cancer cells, said Dr.
1] GRO-08 Freedom red MOR-6 Prestige CD1 MEX-08 Freedom red GRO-4 Prestige CD19 MOR-01 Festival red GRO-7 Prestige CD34 MOR-05 Freedom red GRO-7 Prestige CD42 MOR-21 Freedom red GRO-11 Prestige CD47
MOR-21 Freedom red OAX-10 Prestige CD50 NAY-13 Freedom red GRO-11 Prestige CD70 PUE-07 Freedom red GRO-7 Prestige CD81 SIN-02 Freedom red GRO-7 Prestige CD89 [F.
The performances of activated microglia include: (1) the alteration of cell morphology from the dendritic appearance to ameboid;[sup] (2) The increased expression of surface antigens such as CD14, CD36, CD39, CD45, CD47
, and CD54;[sup], and (3) The accompanied up-regulation of IL-1[sz], TNF-a, and iNOS.
binds to SIRPa on macrophages and delivers a "do not eat" signal that inhibits the ability of macrophages to phagocytose malignant cells.
Temmel, "The C-terminal 26-residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47
," FEBS Letters, vol.
Therapeutic antibody targeting of CD47
eliminates human acute lymphoblastic leukemia.
Other topics include the interaction between signal regulatory protein alpha ad CD47
, malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease, the immunology of relapse and remission in multiple sclerosis, the transcriptional control of early T and B cell development choices, chromatin contributions to the regulation of innate immunity, immunodeficiency associated with an anticytokine autoantibody, chemokines and chemokine receptors: positioning cells for host defense.
2012) Thrombospondin-1 regulates blood flow via CD47
receptor-mediated activation of NADPH oxidase 1.
In 2008, while at NIH, Isenberg was using agents that block a membrane protein called CD47
to explore their effects on blood vessels.
According to Isenberg, "These experiments indicate that we can lake a primary human or other mammalian cell, even a mature adult cell, and by targeting CD47
turn on its pluripotent capability.
The latter is an antibody-like Fc fusion protein that targets the CD47
protein with high affinity, facilitating the elimination of cancer cells and cancer stem cells by the patient's own immune system.